Patent expiries ahead, is India Pharma Inc ready? EP News Bureau Apr 3, 2026 Beyond the semaglutide momentum, a larger wave of patent expiries is set to unfold between 2026 and 2032. For Indian pharma, the…
Redrawing the biopharma map: India’s rise in the biosimilars era Dr Cyrus Karkaria Mar 10, 2026 For India’s biopharma sector, 2025 stood out as an inflection point. The approval of 146 recombinant biosimilar therapeutic…
